Maxim Group Downgrades BioLineRx (BLRX) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TFC
8. TRV
9. USB
10. SPY

Go back to Maxim Group Downgrades BioLineRx (BLRX) to Hold

Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession

August 11, 2016 11:46 AM EDT

Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.

Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More

BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones

August 11, 2016 7:19 AM EDT

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).

Expected upcoming significant milestones for remainder of 2016:

Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3... More